Table 4.
Multivariate Logistic Regression Model: Estimate of the Association Between Patient Characteristics and Risk of Development of Cytopenia, Considering Other Covariates in the Model
| Univariate | Multivariate | ||||
|---|---|---|---|---|---|
| Variable | Effect | P* | Effect | P* | |
| Dose schedule | bid vs qd | .46 | |||
| Splenomegaly | Yes vs no | .13 | |||
| CE | Yes vs no | .75 | |||
| Ph>90% | Yes vs no | .65 | |||
| Prior SCT | Yes vs no | .38 | |||
| Prior IFN | Yes vs no | Worse | .03 | NS | .13 |
| Prior imatinib | Yes vs no | Worse | .05 | NS | .72 |
| Cytogenetic response on imatinib | Yes vs no | .71 | |||
| CML stage | CP vs AP | .72 | |||
| Age | Older | .15 | |||
| CML duration | Longer | Worse | .05 | NS | .25 |
| WBC | Lower | Worse | .04 | NS | .11 |
| PB basophil, % | Higher | .6 | |||
| PB blast, % | Higher | .55 | |||
| BM blast, % | Higher | .75 | |||
| BM basophil, % | Higher | .89 | |||
| Platelets | Lower | .13 | |||
| Hemoglobin | Lower | .17 | |||
| Dasatinib dose | Higher | .47 | |||
bid indicates twice daily; qd, daily; CE, clonal evolution; Ph, Philadelphia chromosome; SCT, stem cell transplantation; IFN, interferon; NS, not significant, CML, chronic myeloid leukemia; CP, chronic phase; AP, accelerated phase; WBC, white blood cell; PB, peripheral blood; BM, bone marrow.
*
Bold type indicates statistical significance.